BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23202930)

  • 1. Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure.
    Weiss I; Trope CG; Reich R; Davidson B
    Int J Mol Sci; 2012 Oct; 13(10):12925-38. PubMed ID: 23202930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan content.
    Nykopp TK; Rilla K; Sironen R; Tammi MI; Tammi RH; Hämäläinen K; Heikkinen AM; Komulainen M; Kosma VM; Anttila M
    BMC Cancer; 2009 May; 9():143. PubMed ID: 19435493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hyaluronan-related genes HAS2, HYAL1-4, PH20 and HYALP1 are associated with prognosis, cell viability and spheroid formation capacity in ovarian cancer.
    Riecks J; Parnigoni A; Győrffy B; Kiesel L; Passi A; Vigetti D; Götte M
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3399-3419. PubMed ID: 35767191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma.
    Nykopp TK; Rilla K; Tammi MI; Tammi RH; Sironen R; Hämäläinen K; Kosma VM; Heinonen S; Anttila M
    BMC Cancer; 2010 Sep; 10():512. PubMed ID: 20875124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival.
    Hetland TE; Nymoen DA; Emilsen E; Kærn J; Tropé CG; Flørenes VA; Davidson B
    Gynecol Oncol; 2012 Sep; 126(3):460-5. PubMed ID: 22652154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.
    Gutgold N; Davidson B; Catane LJ; Holth A; Hellesylt E; Tropé CG; Dørum A; Reich R
    Virchows Arch; 2017 Jun; 470(6):665-678. PubMed ID: 28432432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma.
    Stavnes HT; Nymoen DA; Langerød A; Holth A; Børresen Dale AL; Davidson B
    Virchows Arch; 2013 Feb; 462(2):163-73. PubMed ID: 23242172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
    Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
    Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
    Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B
    Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma.
    Elstrand MB; Kleinberg L; Kohn EC; Tropé CG; Davidson B
    Int J Gynecol Pathol; 2009 May; 28(3):211-21. PubMed ID: 19620938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis.
    Kramer MW; Escudero DO; Lokeshwar SD; Golshani R; Ekwenna OO; Acosta K; Merseburger AS; Soloway M; Lokeshwar VB
    Cancer; 2011 Mar; 117(6):1197-209. PubMed ID: 20960509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance.
    Hetland TE; Nymoen DA; Holth A; Brusegard K; Flørenes VA; Kærn J; Tropé CG; Davidson B
    Hum Pathol; 2013 May; 44(5):777-85. PubMed ID: 23114921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma.
    Davidson B; Nymoen DA; Elgaaen BV; Staff AC; Tropé CG; Kærn J; Reich R; Falkenthal TE
    Virchows Arch; 2014 Jun; 464(6):701-7. PubMed ID: 24756216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression patterns of hyaluronan, hyaluronan synthases and hyaluronidases indicate a role for hyaluronan in the progression of endometrial cancer.
    Paiva P; Van Damme MP; Tellbach M; Jones RL; Jobling T; Salamonsen LA
    Gynecol Oncol; 2005 Aug; 98(2):193-202. PubMed ID: 15936804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyaluronidase splice variants are associated with histology and outcome in adenocarcinoma and squamous cell carcinoma of the lung.
    de Sá VK; Olivieri E; Parra ER; Ab'Saber AM; Takagaki T; Soares FA; Carraro D; Carvalho L; Capelozzi VL
    Hum Pathol; 2012 May; 43(5):675-83. PubMed ID: 21992818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.
    Davidson B; Hadar R; Stavnes HT; Trope' CG; Reich R
    Hum Pathol; 2009 May; 40(5):705-13. PubMed ID: 19157507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
    Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I
    Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival.
    Tuft Stavnes H; Nymoen DA; Hetland Falkenthal TE; Kærn J; Tropé CG; Davidson B
    Am J Clin Pathol; 2014 Jul; 142(1):51-7. PubMed ID: 24926085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival.
    Davidson B; Rosenfeld YB; Holth A; Hellesylt E; Tropé CG; Reich R; Yisraeli JK
    Hum Pathol; 2014 Jul; 45(7):1520-8. PubMed ID: 24814803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
    Broner EC; Tropé CG; Reich R; Davidson B
    Hum Pathol; 2017 Feb; 60():180-187. PubMed ID: 27825812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.